163 related articles for article (PubMed ID: 32236952)
1. Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.
Maliepaard M; Toiviainen T; De Bruin ML; Meulendijks D
Clin Pharmacol Ther; 2020 Aug; 108(2):338-349. PubMed ID: 32236952
[TBL] [Abstract][Full Text] [Related]
2. Functional gene variants of CYP3A4.
Werk AN; Cascorbi I
Clin Pharmacol Ther; 2014 Sep; 96(3):340-8. PubMed ID: 24926778
[TBL] [Abstract][Full Text] [Related]
3. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
4. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates.
Ramsden D; Fung C; Hariparsad N; Kenny JR; Mohutsky M; Parrott NJ; Robertson S; Tweedie DJ
Drug Metab Dispos; 2019 Oct; 47(10):1206-1221. PubMed ID: 31439574
[TBL] [Abstract][Full Text] [Related]
5. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
6. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
Li A; Yeo K; Welty D; Rong H
Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
[TBL] [Abstract][Full Text] [Related]
7. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant.
Hannachi I; Ben Fredj N; Chadli Z; Ben Fadhel N; Ben Romdhane H; Touitou Y; Boughattas NA; Chaabane A; Aouam K
Toxicol Appl Pharmacol; 2020 Jun; 396():115000. PubMed ID: 32275916
[TBL] [Abstract][Full Text] [Related]
10. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
[TBL] [Abstract][Full Text] [Related]
11. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
Niwa T; Murayama N; Emoto C; Yamazaki H
Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
[TBL] [Abstract][Full Text] [Related]
12. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
Kollipara S; Ahmed T; Praveen S
Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
[TBL] [Abstract][Full Text] [Related]
14. The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.
Barve A; Kovacs SJ; Ke J; Crabbe R; Grosgurin P; Menetrey A; Nicolas-Métral V; Dabovic K; Dole K; Zhang J; Praestgaard J; Sunkara G; Stein D
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):25-32. PubMed ID: 27128001
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
Waters NJ
Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
[TBL] [Abstract][Full Text] [Related]
17. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
[TBL] [Abstract][Full Text] [Related]
18. Structure-Property Relationships and Machine Learning Models for Addressing CYP3A4-Mediated Victim Drug-Drug Interaction Risk in Drug Discovery.
Hu B; Zhou X; Mohutsky MA; Desai PV
Mol Pharm; 2020 Sep; 17(9):3600-3608. PubMed ID: 32794756
[TBL] [Abstract][Full Text] [Related]
19. Effect of Chinese herbs on CYP3A4 activity and expression in vitro.
Lau C; Mooiman KD; Maas-Bakker RF; Beijnen JH; Schellens JH; Meijerman I
J Ethnopharmacol; 2013 Sep; 149(2):543-9. PubMed ID: 23876595
[TBL] [Abstract][Full Text] [Related]
20. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
